EditorialBalto, in 1920, an Alaskan sled dog who led his team on the final leg of the 1925 serum run to Nome, Alaska, delivering diphtheria antitoxin to the city, which had been isolated by snow. (via The New York Times Photo Archives)
EditorialBalto, in 1920, an Alaskan sled dog who led his team on the final leg of the 1925 serum run to Nome, Alaska, delivering diphtheria antitoxin to the city, which had been isolated by snow. (via The New York Times Photo Archives)
EditorialBalto, in 1920, an Alaskan sled dog who led his team on the final leg of the 1925 serum run to Nome, Alaska, delivering diphtheria antitoxin to the city, which had been isolated by snow. (via The New York Times Photo Archives)
EditorialBalto, in 1920, an Alaskan sled dog who led his team on the final leg of the 1925 serum run to Nome, Alaska, delivering diphtheria antitoxin to the city, which had been isolated by snow. (via The New York Times Photo Archives)
EditorialHuman finger 1, magnified 2, epidermis 3, magnified 4, scales 5, magnified skin 6, and human blood 7, serum 8, and salt crystals in blood 9 under the microscope. Handcoloured copperplate engraving from Bertuch's "Bilderbuch fur Kinder" (Picture Book fo...
EditorialAnders Rhod Larsen, a microbiologist at Statens Serum Institut in Copenhagen, works with samples of MRSA bacteria, in Denmark, Dec. 12, 2018. (Ciril Jazbec/The New York Times)
EditorialAnders Rhod Larsen, a microbiologist at Statens Serum Institut in Copenhagen, works with samples of MRSA bacteria, in Denmark, Dec. 12, 2018. (Ciril Jazbec/The New York Times)
EditorialA participant in the Novavax vaccine trial at Howard University in Washington receives a dose on Jan. 22, 2021. (Kenny Holston/The New York Times)
EditorialA worker organizes vials of AstraZeneca's Covid-19 vaccine at a Serum Institute of India facility in Pune, India, Sept. 22, 2021. (Karan Deep Singh/The New York Times)
EditorialA worker organizes vials of AstraZeneca's Covid-19 vaccine at a Serum Institute of India facility in Pune, India, Sept. 22, 2021. (Karan Deep Singh/The New York Times)
EditorialA worker organizes vials of AstraZeneca's Covid-19 vaccine at a Serum Institute of India facility in Pune, India, Sept. 22, 2021. (Karan Deep Singh/The New York Times)
EditorialQuality checking during the manufacture of the Covishield vaccine at the Serum Institute in Pune, India, on Jan. 14, 2021. (Atul Loke/The New York Times)
EditorialCovishield coronavirus vaccines undergo inspection at the Serum Institute of India in Pune, India, Jan. 14, 2021. (Atul Loke/The New York Times)